Glaxosmithkline Pharmaceuticals growth ratios

·Pharma & HealthChart ›
ProfitabilityGrowthCreditLiquidityWorking capitalDividend yieldDuPontCAGR
Per cent unless marked ×
Tap a line for its trendFY26Mar 2026FY25Mar 2025FY24Mar 2024FY22 and earlierAlpha Plus
+1.9%+8.6%+6.2%
FY22 and earlierEvery year the company has filed comes with Alpha Plus.
+11.2%+29.6%+13.0%
+11.9%+32.4%+13.6%
+11.7%+57.2%−3.4%
0.0%+56.5%−3.4%
+5.3%+15.5%+6.9%
+17.1%+9.8%+2.1%
−30.0%+121.6%+20.2%
Open the chart

From the company's filings with NSE and BSE (Ind-AS), consolidated. For information only, not investment advice.

GLAXO₹2,515.10

Glaxosmithkline Pharmaceuticals Ltd.

· Pharma & Health
₹ CrorePeersPFIZERABBOTINDIAMEDANTAANTHEMAJANTPHARMIPCALABGLENMARKBIOCONMcap ₹42,608 Cr
ProfitabilityGrowthCreditLiquidityWorking CapitalYield AnalysisDuPont
Ratios — % unless marked ×
12 Months Ending
FY23
31/03/2023
FY24
31/03/2024
FY25
31/03/2025
FY26
31/03/2026
Last 12M
30/06/2026
Revenue Growth—+6.2+8.6+1.9—
EBITDA Growth—+13.0+29.6+11.2—
EBIT Growth—+13.6+32.4+11.9—
Net Income Growth—-3.4+57.2+11.7—
EPS Growth—-3.4+56.50.0—
Total Assets Growth—+6.9+15.5+5.3—
Total Equity Growth—+2.1+9.8+17.1—
Cash from Operations Growth—+20.2+121.6-30.0—
No consensus estimates → no Est columns. Click any row to chart it.
« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.